Janux Therapeutics Inc

JANXNASDAQ · USD
16.30USD0.00 (-2.28%)
435

Janux Therapeutics Inc (JANX) Wheel Strategy

JANX wheel strategy scan found 6 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 38.2%.

Read more

Running a JANX wheel strategy lets you generate consistent premium income on Janux Therapeutics Inc while setting your own entry and exit prices on the underlying. Janux Therapeutics Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own JANX, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best JANX wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on JANX, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable JANX wheel from a losing one.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells.

In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the JANX wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your JANX wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.

Jan 15, 202715.00$1.35$1.78-0.3111352%52.2%38.2%114
Dec 18, 202612.50$0.25$0.78-0.178552%72.6%26.6%236
May 21, 202712.50$0.05$2.13-0.2123952%57.1%26.0%0
Jan 21, 202810.00$0.85$2.93-0.1448452%56.9%22.1%10
Jan 15, 202712.50$0.55$0.83-0.1811352%68.2%21.3%8
Feb 19, 202712.50$0.20$0.93-0.1814852%64.1%18.3%20

As of September 25, 2026

Run the Wheel on JANX With Confidence

Find the best JANX wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.

Start your 14-day free trial